5 research outputs found
Augmented reality–assisted microsurgical resection of brain arteriovenous malformations: illustrative case
Background: Arteriovenous malformations (AVMs) of the brain are vessel conglomerates of feeding arteries and draining veins that carry a risk of spontaneous and intraoperative rupture. Augmented reality (AR)-assisted neuronavigation permits continuous, real-time, updated visualization of navigation information through a heads-up display, thereby potentially improving the safety of surgical resection of AVMs.
Observations: The authors report a case of a 37-year-old female presenting with a 2-year history of recurrent falls due to intermittent right-sided weakness and increasing clumsiness in the right upper extremity. Magnetic resonance imaging, magnetic resonance angiography, and cerebral angiography of the brain revealed a left parietal Spetzler-Martin grade III AVM. After endovascular embolization of the AVM, microsurgical resection using an AR-assisted neuronavigation system was performed. Postoperative angiography confirmed complete obliteration of arteriovenous shunting. The postsurgical course was unremarkable, and the patient remains in excellent health.
Lessons: Our case describes the operative setup and intraoperative employment of AR-assisted neuronavigation for AVM resection. Application of this technology may improve workflow and enhance patient safety
Recommended from our members
Proceedings of the Seventh Annual Deep Brain Stimulation Think Tank: Advances in Neurophysiology, Adaptive DBS, Virtual Reality, Neuroethics and Technology.
The Seventh Annual Deep Brain Stimulation (DBS) Think Tank held on September 8th of 2019 addressed the most current: (1) use and utility of complex neurophysiological signals for development of adaptive neurostimulation to improve clinical outcomes; (2) Advancements in recent neuromodulation techniques to treat neuropsychiatric disorders; (3) New developments in optogenetics and DBS; (4) The use of augmented Virtual reality (VR) and neuromodulation; (5) commercially available technologies; and (6) ethical issues arising in and from research and use of DBS. These advances serve as both "markers of progress" and challenges and opportunities for ongoing address, engagement, and deliberation as we move to improve the functional capabilities and translational value of DBS. It is in this light that these proceedings are presented to inform the field and initiate ongoing discourse. As consistent with the intent, and spirit of this, and prior DBS Think Tanks, the overarching goal is to continue to develop multidisciplinary collaborations to rapidly advance the field and ultimately improve patient outcomes
Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors
The discovery and optimization of a series of 6,7-dihydro-5<i>H</i>-cyclopentaÂ[<i>d</i>]Âpyrimidine compounds that
are ATP-competitive, selective inhibitors of protein kinase B/Akt
is reported. The initial design and optimization was guided by the
use of X-ray structures of inhibitors in complex with Akt1 and the
closely related protein kinase A. The resulting compounds demonstrate
potent inhibition of all three Akt isoforms in biochemical assays
and poor inhibition of other members of the cAMP-dependent protein
kinase/protein kinase G/protein kinase C extended family and block
the phosphorylation of multiple downstream targets of Akt in human
cancer cell lines. Biological studies with one such compound, <b>28</b> (GDC-0068), demonstrate good oral exposure resulting in
dose-dependent pharmacodynamic effects on downstream biomarkers and
a robust antitumor response in xenograft models in which the phosphatidylinositol
3-kinase–Akt–mammalian target of rapamycin pathway is
activated. <b>28</b> is currently being evaluated in human clinical
trials for the treatment of cancer